LICENSE AGREEMENT MICHIGAN FILE 492p2 TECHNOLOGY

BACKGROUND.

Michigan (in part in the Howard Hughes Medical Institute (“HHMI”) laboratories at MICHIGAN) and the Research Institute of the Hospital for Sick Children of Toronto, Ontario, Canada, (“HSC”) have conducted research relating to cystic fibrosis. As a result of that research, MICHIGAN arid RDLP have developed rights in the “Licensed Patent(s)” defined below.

LICENSEE desires to obtain, and MICHIGAN and RDLP, consistent with their missions of education and research, desire to grant a license of the “Licensed Patent(s)” on the terms and conditions listed below.

MICHIGAN and RDLP have entered into a Memorandum of Agreement covering the Licensed Patent(s), consistent with which MICHIGAN and RDLP are entering into this License Agreement jointly as the licensor of the Licensed Patent(s).

DEFINITIONS.

“TECHNOLOGY”, as used in this Agreement, shall mean the information, manufacturing techniques, data, designs or concepts developed by MICHIGAN and HSC, covering the gene for cystic fibrosis and uses thereof as covered by the claims of U.S. Patent Nos. 5,776,677 and 6,984,487 entitled “Cystic Fibrosis Gene.”

“Parties”, in singular or plural usage as required by the context, shall mean LICENSEE, MICHIGAN and/or RDLP.

“Affiliate(s)” shall mean any individual, corporation, partnership, proprietorship or other entity controlled by, controlling, or under common control with LICENSEE through equity ownership, ability to elect directors, or by virtue of a majority of overlapping directors, and shall include any individual, corporation, partnership, proprietorship or other entity directly or indirectly owning, owned by or under common ownership with LICENSEE to the extent of fifty percent (50%) or more of the voting shares, including shares owned beneficially by such party.

“Licensed Patent(s)” shall mean U.S. Patent Nos. 5,776,677 and 6,984,487, entitled “Cystic Fibrosis Gene” and all foreign equivalent patent applications and Patent Cooperation Treaty filings, and all patents issuing therefrom in which Michigan and/or RDLP has or acquires a property interest (currently including the applications listed in the Appendix I attached to this Agreement). “Licensed Patent(s)” shall also include any divisional, continuation (excluding continuations-in-part), reissue, reexamination or extension of the above-described patent applications and resulting patents, along with any extended or restored term, and any confirmation patent, registration patent or patent of addition.

“Valid Claim(s)” means any claim(s) in an unexpired patent or pending in a patent application included within the Licensed Patent(s) which has not been held unenforceable, unpatentable, or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and which has not been admitted to be invalid or unenforceable through reissue or disclaimer. If in any country there should be two or more such decisions conflicting with respect to the validity of the same claim, the decision of the higher or highest tribunal shall thereafter control; however, should the tribunals be of equal rank, then the decision or decisions upholding the claim shall prevail when the conflicting decisions are equal in number, and the majority of decisions shall prevail When the conflicting decisions are unequal in number.

“Product(s)” shall mean any product(s) whose manufacture, use or sale in any country would, but for this Agreement, comprise an infringement, including contributory infringement, of one or more Valid Claims.

“Field of Use” shall refer to the field for which Product(s) may be designed, manufactured, used and/or marketed under this Agreement, and shall mean solely Product(s) to be used for the research of, diagnosis of and screening for the disease cystic fibrosis.

“Net Sales” shall mean the sum, over the term of this Agreement, of all amounts received and all other consideration received (or, when in a form other than cash or its equivalent, the fair market value thereof when received) by LICENSEE and its Affiliates from persons or entities due to or by reason of the sale or other distribution of Product(s), or the use of Product(s), including any use by LICENSEE and Affiliates in the performance of services for their customers; less the following deductions and offsets, but only to the extent such sums are otherwise included in the computation of Net Sales, or are paid-by LICENSEE and not otherwise reimbursed: refunds, rebates, replacements or credits actually allowed and taken by purchasers for return of Product(s); customary trade, quantity and cash discounts actually allowed and taken; excise, value-added, and sales taxes actually paid by LICENSEE for Product(s); and shipping and handling charges actually paid by LICENSEE for Product(s).

“Royalty Quarter(s)” shall mean the three month periods ending on the last day of March, June, September and December of each year.

“Territory” means all countries of the world.

“First Diagnostic Sale” shall mean the first sale of any Product (including any sale of a service using a Product in the Field of Use) by LICENSEE or an Affiliate, other than for use in clinical trials being conducted to obtain FDA or other governmental approvals to market Product(s).

GRANT OF LICENSE.

MICHIGAN and RDLP hereby grant to LICENSEE a non-exclusive license under the Licensed Patent(s) and TECHNOLOGY to make, have made, use (including use in the performance of services for, by or on behalf of its customers), have used, import, market and/or sell, in the Territory, Product(s) designed and marketed solely for use in the Field of Use.

MICHIGAN and RDLP reserve the right to license and use all aspects of the TECHNOLOGY and the Licensed Patent(s) for any use or purpose, including the right to develop and produce Product(s).

The license granted to LICENSEE herein shall be without the right to sublicense, except that LICENSEE may sublicense Affiliate(s) who agree to be and are bound in writing to the terms and conditions of this Agreement to the same extent as LICENSEE. LICENSEE agrees to strictly monitor and enforce compliance with the terms and conditions of this Agreement by all Affiliate sublicensees.

CONSIDERATION.

LICENSEE shall pay to MICHIGAN a one-time, non-creditable license issue fee of             ***            , forthwith following the Effective Date. Notwithstanding any other terms of this Agreement, this Agreement and the license granted hereunder shall not become effective until such issue fee is received by MICHIGAN.

LICENSEE shall also pay MICHIGAN, with respect to each Royalty Quarter, a royalty equal to             ***             of the Net Sales of Product(s) of LICENSEE and Affiliates during such Royalty Quarter.

The obligation to pay MICHIGAN a royalty under this Article 4 is imposed only once with respect to the same unit of Product regardless of the number of Valid Claims or Licensed Patent(s) covering the same; however, for purposes of determination of payments due hereunder, whenever the term “Product” may apply to a property during various stages of manufacture, use or sale, Net Sales, as otherwise defined, shall be derived from the sale, distribution or use of such Product by LICENSEE or Affiliates at the stage of its highest invoiced value to unrelated third parties.

Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission.

LICENSEE shall pay to MICHIGAN an annual license maintenance fee. This annual fee shall accrue in the Royalty Quarter ending in March of the years specified below, and shall be due and payable and included with the report for that quarter.

In 2006 and in each year thereafter during the term of this Agreement up to and including the year in which LICENSEE first obtains FDA approval or other governmental approval to distribute or use Product(s) in the Field of Use:             ***            .

In the first calendar year following the year in which LICENSEE obtains the approval described in (1) above, and in each year thereafter during the term of this Agreement up to and including the year in which the First Diagnostic Sale occurs:             ***        ;

In the first calendar year following the First Diagnostic Sale:             ***        ;

In the second year following the First Diagnostic Sale:             ***        ;

In the third year following the First Diagnostic Sale:             ***        ; and

In the fourth year following the First Diagnostic Sale, and in each year thereafter during the term of this Agreement;            ***            .

If LICENSEE takes any license(s), in a given country, under valid third party patents (i.e., those held by a licensor that is not an Affiliate of LICENSEE) which would be

Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission.

infringed by the manufacture, use or sale of Product(s) in that country, then LICENSEE can deduct up to             ***             of the royalties otherwise due and payable in each Royalty Quarter under Paragraph 4.2 above for Net Sales in that country, until such time as LICENSEE has recovered an amount equal to             ***             of the royalty paid to such third parties; provided that in no event shall such deducted amounts be applied to reduce or require reimbursement of the annual fees required under Paragraph 4.4. This Paragraph is not intended to imply an obligation upon MICHIGAN or RDLP to reimburse LICENSEE’S above-described third-party royalties; the rights granted to LICENSEE in this Paragraph shall not exceed the ability of the above-described mechanism (i.e., a deduction of             ***             of royalties due upon Net Sales in the country in question) to reimburse such expenses. LICENSEE shall make an accounting to MICHIGAN of all such third-party royalties, and all resulting deductions from royalties otherwise due and payable to MICHIGAN, as part of its reporting obligations under Article 5 below.

If MICHIGAN and RDLP grant a license under the Licensed Patent(s) and in the Field of Use to any third party which is substantially the same as the license granted to LICENSEE under Article 3 above, for all or any part of the Territory, but which requires a royalty rate or license maintenance fees lower than those required of LICENSEE under this Agreement, then MICHIGAN and RDLP shall offer those terms to LICENSEE for that part of the Territory, to be effective as of the effective date of the license to that third party.

REPORTS.

Within sixty (60) days after the close of (i) any Royalty Quarter in which a fee under Paragraph 4.4 accrues, and (ii) each Royalty Quarter following the First Diagnostic Sale during the term of this Agreement (including the close of any Royalty Quarter immediately following any termination of this Agreement), LICENSEE shall report to MICHIGAN all royalties accruing to MICHIGAN during such Royalty Quarter. Such quarterly reports shall indicate for each Royalty Quarter the gross sales and Net Sales of Product(s) by LICENSEE and Affiliates, and any other revenues with respect to which payments are due, and the amount of such payments, as well as the various calculations used to arrive at said amounts, including the quantity, description (nomenclature and type designation), country of manufacture and country of sale of Product(s). In case no payment is due for any such period, LICENSEE shall so report.

LICENSEE covenants that it will promptly establish and consistently employ a system of specific nomenclature and type designations for Product(s) so that various types can be identified and segregated, where necessary; LICENSEE and Affiliates shall consistently employ such system when rendering invoices thereon and henceforth agree to inform MICHIGAN, or its auditors, when requested as to the details concerning such nomenclature system as well as to all additions thereto and changes therein.

Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission.

LICENSEE shall keep, and shall require its Affiliates to keep, true and accurate records and books of account containing data reasonably required for the computation and verification of payments to be made as provided by this Agreement, which records and books shall be open for inspection upon reasonable notice during business hours by an independent certified accountant selected by MICHIGAN, for the purpose of verifying the amount of payments due and payable. Said right of inspection will exist for six (6) years from the date of origination of any such record, and this requirement and right of inspection shall survive any expiration or termination of this Agreement MICHIGAN shall be responsible for all expenses of such inspection, except that if such inspection reveals an underpayment of royalties to MICHIGAN in excess of             ***             for any year, then said inspection shall be at LICENSEE’S expense and such underpayment shall become immediately due and payable to MICHIGAN.

The reports provided for hereunder shall be certified by an authorized representative of LICENSEE to be correct to the best of LICENSEE’S knowledge and information.

TIMES AND CURRENCIES OF PAYMENTS.

Payments accrued during each Royalty Quarter shall be due and payable in Ann Arbor, Michigan on the date each quarterly report is due (as provided in Paragraph 5.1). LICENSEE will send the report and notice of payment by prepaid, certified or registered mail, return receipt requested, to the address for notices set forth in Article 19 herein. PAYMENTS shall be paid in United States dollars. LICENSEE shall be responsible for the payment of charges imposed by any bank with respect to payments made to MICHIGAN under this agreement by direct deposit. LICENSEE agrees to make all payments due hereunder to MICHIGAN by direct deposit to account:

On all undisputed amounts outstanding and payable to MICHIGAN, interest shall accrue from the date such amounts are due and payable at             ***             above the prime lending rate as established by the Chase Manhattan Bank, N.A., in New York City, New York, or at such lower rate as may be required by law.

Where Net Sales are generated in foreign currency, such foreign currency shall be converted into its equivalent in United States dollars at the exchange rate of such currency as reported (or if erroneously reported, as subsequently corrected) in the Wall Street Journal on the day that the sale is made by LICENSEE or Affiliates (or if not reported on that date, as quoted by the Chase Manhattan Bank, N.A., in New York City, New York).

Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission.

Except as provided in the definition of Net Sales, all royalty payments to MICHIGAN under this Agreement shall be without deduction for sales, use, excise, personal property or other similar taxes or other duties imposed on such payments by the government of any country or any political subdivision thereof; and any and all such taxes or duties shall be assumed by and paid by LICENSEE.

COMMERCIALIZATION.

It is understood that LICENSEE has the responsibility to do all that is necessary for any governmental approvals to manufacture and/or sell Product(s).

LICENSEE agrees to use reasonable efforts to develop Product(s), obtain any government approvals necessary, and manufacture and sell Product(s) at the earliest possible date; and to effectively exploit, market and manufacture in sufficient quantities to meet anticipated customer demand and to make the benefits of the Product(s) reasonably available to the public.

Within thirty (30) days of the First Diagnostic Sale, LICENSEE shall report by written letter to MICHIGAN the date of that sale.

PATENT APPLICATIONS AND MAINTENANCE.

MICHIGAN and RDLP shall control all aspects of filing, prosecuting, and maintaining Licensed Patent(s), including foreign filings and Patent Cooperation Treaty filings. MICHIGAN and RDLP may in their sole discretion decide to refrain from or to cease prosecuting or maintaining any of the Licensed Patent(s), including any foreign filing or any Patent Cooperation Treaty filing.

MICHIGAN shall notify LICENSEE of any issuance of any Licensed Patent(s) and the Valid Claims included therein, and any lapse, revocation, surrender, invalidation or abandonment of any Licensed Patent or Valid Claim.

INFRINGEMENT.

If LICENSEE becomes aware of or reasonably suspects infringement of Licensed Patent(s) by third parties, LICENSEE agrees to promptly notify MICHIGAN of such alleged infringement.

MICHIGAN and RDLP, at their sole discretion and at their own expense, may initiate proceedings in response to alleged infringement of Licensed Patent(s), but are under no obligation to do so.

NO WARRANTIES: LIMITATION ON MICHIGAN’S AND RDLP’S LIABILITY.

MICHIGAN and RDLP, including their fellows, directors, officers, employees and agents, make no representations or warranties that any Licensed Patent is or will be held valid, or that the manufacture, use, sale or other distribution of any Product(s) will not infringe upon any patent or other rights not vested in MICHIGAN or RDLP.

MICHIGAN, HSC AND RDLP, INCLUDING THEIR FELLOWS, DIRECTORS, OFFICERS, EMPLOYEES AND AGENTS, MAKE NO REPRESENTATIONS, EXTEND NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, AND ASSUME NO RESPONSIBILITIES WHATEVER WITH RESPECT TO DESIGN, DEVELOPMENT, MANUFACTURE, USE, SALE OR OTHER DISPOSITION BY LICENSEE OR AFFILIATES OF PRODUCT(S).

THE ENTIRE RISK AS TO THE DESIGN, DEVELOPMENT, MANUFACTURE, OFFERING FOR SALE, SALE OR OTHER DISPOSITION, AND PERFORMANCE OF PRODUCT(S) IS ASSUMED BY LICENSEE AND AFFILIATES. In no event shall MICHIGAN, RDLP or HSC, including their fellows, directors, officers, employees and agents, be responsible or liable for any direct, indirect, special, incidental, or consequential damages or lost profits to LICENSEE, Affiliates or any other individual or entity regardless of legal theory. The above limitations on liability apply even though MICHIGAN, HHMI, RDLP, or HSC, including their fellows, directors, officers, employees or agents, may have been advised of the possibility of such damage.

LICENSEE shall not, and shall require that its Affiliates do not, make any statements, representations or warranties or accept any liabilities or responsibilities whatsoever to or with regard to any person or entity which are inconsistent with any disclaimer or limitation included in this Article 10.

Regardless of any research or testing that may have been done at HSC or MICHIGAN (including HHMI laboratories), HSC, MICHIGAN, and RDLP make no representations regarding how Product(s) can or should be used in the diagnosis of and screening for the disease cystic fibrosis.

IT IS UNDERSTOOD THAT THE TECHNOLOGY AND THE LICENSED PATENT(S) DO NOT IDENTIFY THE PRESENCE OF THE CYSTIC FIBROSIS DISEASE IN ALL CASES.

INDEMNITY; INSURANCE.

LICENSEE shall defend, indemnity and hold harmless and shall require its Affiliates licensed hereunder to defend, indemnify and hold harmless MICHIGAN, RDLP and HSC, as well as their fellows, officers, trustees, directors, employees and agents, from and against any and all claims, demands, damages, losses, and expenses of any nature (including attorneys’ fees and other litigation expenses), resulting from, but not limited to, death, personal injury, illness, property damage, economic loss or products liability arising from or in connection with, any of the following:

Any manufacture, use, sale or other disposition by LICENSEE, Affiliates or transferees of Product(s);

The direct or indirect use by any person of Product(s) made, used, sold or otherwise distributed by LICENSEE or Affiliates;

The use by LICENSEE or Affiliates of any invention included in the TECHNOLOGY or the Licensed Patent(s).

MICHIGAN and RDLP shall be entitled to participate at their option and expense through counsel of their own selection, and may join in any legal actions related to any such claims, demands, damages, losses and expenses under Paragraph 11.1 above, provided that LICENSEE will retain control over such legal actions, including any settlement discussions.

HHMI and its trustees, officers, employees, and agents (collectively, “HHMI Indemnitees”), will be indemnified, defended by counsel reasonably acceptable to HHMI, and held harmless by the Licensee from and against any claim, liability, cost, expense, damage, deficiency, loss, or obligation, of any kind or nature (including, without limitation, reasonable attorneys’ fees and other costs and expenses of defense) (collectively, “Claims”), based upon, arising out of, or otherwise relating to this License Agreement, including without limitation any cause of action relating to product liability. The previous sentence will not apply to any Claim that is determined with finality by a court of competent jurisdiction to result from the gross negligence or willful misconduct of an HHMI Indemnitee.

LICENSEE shall purchase and maintain in effect a policy of product liability insurance covering all claims with respect to diagnostic testing for cystic fibrosis using a Product and any Product(s) manufactured, sold, licensed or otherwise distributed by LICENSEE and Affiliates. Such insurance policy must specify MICHIGAN, HHMI, RDLP and HSC, including their fellows, officers, trustees, directors, Regents, agents and employees, as an additional insureds. LICENSEE shall furnish certificate(s) of such insurance to MICHIGAN, upon request.

TERM AND TERMINATION.

Upon any termination of this Agreement, and except as provided herein to the contrary, all rights and obligations of the Parties hereunder shall cease, except as follows:

Obligations to pay royalties and other sums accruing hereunder up to the day of such termination;

MICHIGAN’s rights to inspect books and records as described in Article 5, and LICENSEE’s obligations to keep such records for the required time;

Obligations of defense and indemnity under Article 11;

Any cause of action or claim of LICENSEE or MICHIGAN or RDLP accrued or to accrue because of any breach of default by another Party hereunder;

The general rights, obligations, and understandings of Articles 2, 10, 15, 17, 26, 27, and 28;

All other terms, provisions, representations, rights and obligations contained in this Agreement that by their sense and context are intended to survive until performance thereof.

This Agreement will become effective on its Effective Date and, unless terminated under another, specific provision of this Agreement, will remain in effect until and terminate upon the last to expire of Licensed Patent(s).

If LICENSEE shall at any time default in the payment of any royalty or the making of any report hereunder, or shall make any false report, or shall commit any material breach of any covenant or promise herein contained, and shall fail to remedy any such default, breach or report within sixty (60) days after written notice thereof by MICHIGAN specifying such default, then MICHIGAN and RDLP may, at their option, terminate this Agreement and the license rights granted herein by notice in writing to such effect. Any such termination shall be without prejudice to any Party’s other legal rights for breach of this Agreement.

LICENSEE may terminate this Agreement by giving MICHIGAN a notice of termination, which shall include a statement of the reasons, whatever they may be, for such termination and the termination date established by LICENSEE, which date shall not be sooner than ninety (90) days after the date of the notice. Such notice shall be deemed by the Parties to be final.

In the event LICENSEE shall at any time during the term of this Agreement deal with the TECHNOLOGY or Product(s) in any manner which violates the laws, regulations or similar legal authority of any jurisdiction including, but not limited to, the public health requirements relating to the TECHNOLOGY or Product(s) or the design, development, manufacture, offering for sale, sale or other disposition of Product(s), the license granted herein shall terminate immediately with respect to such Product(s) within the territory encompassed by such jurisdiction provided that LICENSEE has failed to take steps to cure such violation within sixty (60) days after receiving written notice from the applicable legal authority.

ASSIGNMENT.

REGISTRATION AND RECORDATION.

If the terms of this Agreement, or any assignment or license under this Agreement are or become such as to require that the Agreement or license or any part thereof be registered with or reported to a national or supranational agency of any area in which LICENSEE or Affiliates would do business, LICENSEE will, at its expense, undertake such registration or report. Prompt notice and appropriate verification of the act of registration or report or any agency ruling resulting from it will be supplied by LICENSEE to MICHIGAN.

Any formal recordation of this Agreement or any license herein granted which is required by the law of any country, as a prerequisite to enforceability of the Agreement or license in the courts of any such country or for other reasons, shall also be carried out by LICENSEE at its expense, and appropriately verified proof of recordation shall be promptly furnished to MICHIGAN.

LAWS AND REGULATIONS OF THE UNITED STATES AND CANADA; EXPORT.

Activities under this Agreement shall be subject to all appropriate United States and Canadian laws and regulations now or hereafter applicable.

LICENSEE shall comply, and shall require its Affiliates to comply, with all provisions of any applicable laws, regulations, rules and orders relating to the license herein granted and to the testing, production, transportation, export, packaging, labeling, sale or use of Product(s), or otherwise applicable to LICENSEE’S or its Affiliates’ activities hereunder.

LICENSEE shall obtain, and shall require its Affiliates to obtain, such written assurances regarding export and re-export of technical data (including Product(s) made by use of technical data) as may be required by the United States Office of Export Administration Regulations, and LICENSEE hereby gives such written assurances as may be required under those Regulations to MICHIGAN.

LICENSEE shall obtain, and shall require its Affiliates to obtain, such authorization regarding export and re-export of technical data (including Product(s) made by use of technical data) as may be required by the Department of External Affairs, Export Controls Division, or any authorization necessary for export from or import into Canada, and LICENSEE hereby gives written assurances as may be required under those regulations to RDLP.

BANKRUPTCY.

PUBLICITY.

PRODUCT MARKING.

NOTICES.

To LICENSEE:

Clinical Micro Sensors

DBA Osmetech Molecular Diagnostics

757 South Raymond Avenue

Pasadena, CA 91105 USA

Attn: President

To MICHIGAN:

The University of Michigan

Technology Management Office

Wolverine Tower, Room 2071

3003 South State Street

Ann Arbor, MI 48109-1280

U.S.A.

Attn.: File No. 492p2

with a copy to:

HSC Research and Development

Limited Partnership

555 University Avenue

Suite 5270

Toronto, Ontario M5G 1X8

CANADA

Attn.: President

INVALIDITY.

ENTIRE AGREEMENT AND AMENDMENTS.

WAIVER.

ARTICLE HEADINGS.

NO AGENCY RELATIONSHIP.

FORCE MAJEURE.

GOVERNING LAW.

JURISDICTION AND FORUM.

HHMI THIRD PARTY BENEFICIARY STATUS

FOR LICENSEE

By

/s/ Bruce A. Huebner

(authorized representative)

Typed Name

Bruce A. Huebner

Title

President

Date

3/22/06

FOR HSC RESEARCH AND

DEVELOPMENT THE LIMITED

PARTNERSHIP

FOR THE REGENTS OF

UNIVERSITY OF MICHIGAN

By:

/s/ Stuart D. Howe

By

/s/ Kenneth J. Nisbet

(authorized representative)

(authorized representative)

Typed Name

Stuart D. Howe, Ph.D.

Typed Name

Kenneth J. Nisbet

President

HSC Research and Development

Limited Partnership

555 University Avenue

Title

Date

Executive Director

UM Technology Transfer

3/24/06

Title

Toronto, Ontario, M5G 1XB

Date

Mar 28, 06

Title:

Cystic Fibrosis Gene

Inventors:

Tsui, Riordan, Collins, Rommens, Iannuzzi, Kerem, Drumm, Buchwald,

Abstract:

The cystic fibrosis gene and its gene product are described for both the normal and mutant forms. The genetic and protein information is used in developing DNA diagnosis, protein diagnosis, carrier and patient screening, drug and gene therapy, cloning of the gene and manufacture of the protein, and development of cystic fibrosis affected animals.

Number

Date Filed

United States

07/396,894

abandoned

United States

07/399,945

abandoned

United States

07/401,609

31/08/89

US Continuation ⁽⁶⁾

08/123,864

20/09/93

US Divisional ⁽⁷⁾

08/252,778

2/06/94

US Divisional ⁽³⁾

08/446,866

6/06/95

US Divisional

08/471,654

abandoned

US Divisional

08/466,897

abandoned

US Divisional ⁽⁵⁾

08/469,630

6/06/95

US Divisional ⁽⁴⁾

08/469,617

6/06/95

Ireland ⁽²⁾

3024/90

21/08/90

PCT

CA90/00267

WO 91/02796

20/08/90

7/03/91

EPO ⁽¹⁾

90912428.1

20/08/90

Japan

511424/90

20/08/90

Japan Divisional

029998/04

5/03/04

Canada

2066204-2

20/08/90

Australia ⁽²⁾

61616/90

20/08/90

Date Issued

⁽¹⁾ EPO ^*

0489058

5/11/03

⁽²⁾ Australia granted

647,408

25/01/94

⁽³⁾ US issued

5,776,677

7/07/98

⁽⁴⁾ US issued

6,201,107

13/03/01

⁽⁵⁾ US issued

6,730,777

4/05/04

⁽⁶⁾ US issued

6,984,487

10/01/06

⁽⁷⁾ US issued

6,902,907

7/06/05

⁽⁸⁾ Ireland granted

83911

6/05/05

Designated States include the following countries: Austria, Belgium, Switzerland and Liechtenstein, Germany, Denmark, Spain, France, United Kingdom, Italy, Luxembourg, Netherlands, Sweden